Avoro Capital Advisors Reduces $47M in Vaxcyte, Inc. ($PCVX)

Avoro Capital Advisors has sold its entire stake in Vaxcyte, Inc., removing 1 million shares from its portfolio.

Written by Trueearnings · Published Jun 13, 2026, 5:36 AM EDT · Updated Jun 14, 2026, 4:55 AM EDT

Key Points

Avoro Capital Advisors completely exited its Vaxcyte, Inc. position, selling 1 million shares as of the latest SEC filing.
Vaxcyte's stock price recently traded at $47.46, with a market capitalization of approximately $6.85 billion.
Several peer funds like Janus Henderson and FMR LLC increased their holdings in Vaxcyte, Inc.

Avoro Capital Advisors has completely sold its stake in Vaxcyte, Inc. (NasdaqGS: PCVX), according to its latest filing with the SEC on August 14, 2025. The fund cut 1 million shares, leaving it with no remaining shares in the clinical-stage vaccine company.

What Changed in Avoro Capital Advisors' Vaxcyte Position

Avoro Capital Advisors decided to exit its position in Vaxcyte, Inc., selling off its entire holding of 1 million shares. This move marks a 100% reduction in its stake, as the fund previously held 1 million shares in the biotech company.

Other Institutional Activity in Vaxcyte

Other institutional investors have been active in Vaxcyte as well. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at about $960.2 million. Similarly, FMR LLC added 2,658,347 shares, now holding 16,492,861 shares worth approximately $958.4 million. T. Rowe Price Investment Management, Inc. also boosted its position by 829,684 shares, reaching a total of 12,126,017 shares valued at $704.6 million. Meanwhile, RA Capital Management, L.P. and BlackRock, Inc. increased their holdings by 750,000 and 725,438 shares, respectively.

Vaxcyte, Inc. Stock Snapshot

Shares of Vaxcyte, Inc. recently traded around $47.46. The company has a market cap of approximately $6.85 billion. Vaxcyte isn't currently profitable, as indicated by its negative forward P/E ratio of -6.39. The stock has experienced a 52-week low of $29.08 and a high of $65.00. Its 50-day moving average is $54.48, while the 200-day moving average stands at $48.67. The company maintains a robust current ratio of 7.49 and a quick ratio of 7.18, with a debt-to-equity ratio of 3.88.

Insider Buying and Selling at Vaxcyte, Inc.

Recent insider transactions include planned sales by Jim Wassil, the Chief Operating Officer, who sold 2,250 shares on June 1, 2026, at an average price of $49.52. Earlier, Wassil sold the same amount on May 1, 2026, at $56.83, and on April 1, 2026, at $58.43. Elvia Cowan, SVP of Finance & CAO, sold 3,000 shares on April 7, 2026, at $60.00, with a separate buy of 3,000 shares on the same day at $25.92.

Analysts Set New Price Targets

On February 26, 2026, BTIG maintained its buy rating on Vaxcyte with an $89.00 price target. Guggenheim reiterated its buy rating on February 2, 2026, with a target of $116.00. Needham also maintained a buy rating on January 7, 2026, setting a target of $110.00. Analysts overall have a strong buy consensus, with an average target price of $109.00 from nine opinions.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a biotech company based in San Carlos, California, focused on developing innovative vaccines to combat bacterial infectious diseases. Their lead product, VAX-24, is a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. Vaxcyte also works on other vaccine candidates targeting various infectious diseases. The company was founded in 2013 and is led by CEO Grant Pickering.

Bottom Line

Avoro Capital Advisors' exit from Vaxcyte, Inc. reflects its investment strategy as of the reporting period, though it doesn't necessarily indicate current holdings. Investors watch these 13F filings closely for insights into institutional sentiment. Vaxcyte remains a significant player in the vaccine innovation space, attracting attention from other major funds and analysts alike.